Evidence map›Paper›PMID 35539193›Full record

ArticleRSC advances2018

Discovery of acylphloroglucinol-based meroterpenoid enantiomers as KSHV inhibitors from

Linzhen Hu, Yanfei Liu, Yanxing Wang, Zhenzhen Wang, Jinfeng Huang, Yongbo Xue, Junjun Liu, Zhenming Liu, Yong Chen, Yonghui Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Linzhen HuNational & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei Key Laboratory of Biotechnology of Chinese Traditional Medicine, School of Life Sciences, Hubei University Wuhan 430062 Hubei Province P. R. China cy101610@qq.com.ORCID https://orcid.org/0000-0002-9090-3179
Yanfei LiuThe Central Hospital of Wuhan, Huazhong University of Science and Technology Wuhan 430014 Hubei Province P. R. China.
Yanxing WangState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Beijing 100191 P. R. China zmliu@bjmu.edu.cn.
Zhenzhen WangHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030 Hubei Province P. R. China zhangyh@mails.tjmu.edu.cn.
Jinfeng HuangHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030 Hubei Province P. R. China zhangyh@mails.tjmu.edu.cn.
Yongbo XueHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030 Hubei Province P. R. China zhangyh@mails.tjmu.edu.cn.
Junjun LiuHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030 Hubei Province P. R. China zhangyh@mails.tjmu.edu.cn.ORCID https://orcid.org/0000-0001-9953-8633
Zhenming LiuState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Beijing 100191 P. R. China zmliu@bjmu.edu.cn.
Yong ChenNational & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei Key Laboratory of Biotechnology of Chinese Traditional Medicine, School of Life Sciences, Hubei University Wuhan 430062 Hubei Province P. R. China cy101610@qq.com.
Yonghui ZhangHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030 Hubei Province P. R. China zhangyh@mails.tjmu.edu.cn.ORCID https://orcid.org/0000-0002-7222-2142

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kaposi's sarcoma associated herpesvirus (KSHV) has gained considerable attention as a type of carcinogenic pathogen. Recent research suggests that KSHV has participated in the pathogenesis of Kaposi's sarcoma-related malignant neoplastic diseases. Viral lytic infection might be pivotal for the etiopathogenesis of KSHV-induced diseases; however, most clinical KSHV lytic replication inhibitors like ganciclovir, nelfinavir, or cidofovir do not restrain virus replication effectively enough to achieve clinical efficacy. In our continued pharmaceutical studies on Chinese herbal medicines, new acylphloroglucinol-based meroterpenoid enantiomers have been discovered from

Identifiers

PMID35539193
PMCPMC9081833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.